SB-649868

SB-649868 is a dual orexin receptor antagonist that was being developed by GlaxoSmithKline as a treatment for insomnia.[1]

SB-649868
Clinical data
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • N-([(2S)-1-([5-(4-fluorophenyl)-2-methyl-4-thiazolyl]carbonyl)-2-piperidinyl]methyl)-4-benzofurancarboxamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H24FN3O3S
Molar mass477.55 g·mol−1
3D model (JSmol)
SMILES
  • CC1=NC(=C(S1)C2=CC=C(C=C2)F)C(=O)N3CCCC[C@H]3CNC(=O)C4=C5C=COC5=CC=C4
InChI
  • InChI=1S/C26H24FN3O3S/c1-16-29-23(24(34-16)17-8-10-18(27)11-9-17)26(32)30-13-3-2-5-19(30)15-28-25(31)21-6-4-7-22-20(21)12-14-33-22/h4,6-12,14,19H,2-3,5,13,15H2,1H3,(H,28,31)/t19-/m0/s1
  • Key:ZJXIUGNEAIHSBI-IBGZPJMESA-N

A phase I clinical trial evaluated doses up to 80 mg, resulting in significant improvement in sleep latency without adverse effects.[2] In randomized, double-blind, placebo-controlled crossover trials, the 10 and 30 mg doses increased sleep time and reduced sleep latency.[3] The subsequent phase II study added a 60 mg dose and observed dose-dependent sleep promotion.[4]

The compound no longer appears to be under active development, with the last study posted to ClinicalTrials.gov completed in 2010.

See also

References

  1. Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, et al. (February 2011). "Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans". Drug Metabolism and Disposition. 39 (2): 215–27. doi:10.1124/dmd.110.035386. PMID 21045199. S2CID 1995624.
  2. Bettica P, Nucci G, Pyke C, Squassante L, Zamuner S, Ratti E, et al. (August 2012). "Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist". Journal of Psychopharmacology. 26 (8): 1058–70. doi:10.1177/0269881111408954. PMID 21730017. S2CID 29578953.
  3. Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, Dijk DJ (April 2012). "Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia". Neuropsychopharmacology. 37 (5): 1224–33. doi:10.1038/npp.2011.310. PMC 3306884. PMID 22237311.
  4. Bettica P, Squassante L, Zamuner S, Nucci G, Danker-Hopfe H, Ratti E (August 2012). "The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia". Sleep. 35 (8): 1097–104. doi:10.5665/sleep.1996. PMC 3397789. PMID 22851805.

Further reading

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.